RobertMurphyMD

PubMed

• 50 citations
  Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362
  Susan E. Cohn, Hongyu Jiang, J. Allen McCutchan, Susan L. Koletar, Robert L. Murphy
  AIDS Care. 2011-02-02
• 265 citations
  Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
  Gregory K. Robbins, Victor De Gruttola, Robert W. Shafer, Laura M. Smeaton, Sally Snyder
  The New England Journal of Medicine. 2003-12-11
• 409 citations
  Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection
  Roy M. Gulick, Heather J. Ribaudo, Cecilia M. Shikuma, Stephanie Lustgarten, Kathleen Squires
  The New England Journal of Medicine. 2004-04-29

Journal Articles

• Enhancement of health research capacity in Nigeria through North-South and in-country partnerships  
  Olaleye DO, Odaibo GN, Carney P, Agbaji O, Sagay AS, Muktar H, Akinyinka OO, Omigbodyn AO, Ogunniyi A, Gashau W, Akanmu S, Ogunsola F, Chukwuka C, Okonkwo PI, Meloni S..., Acad Med, 1/1/2014
• Comparison of auditory brainstem response in HIV-1 exposed newborns and correlation with the maternal viral load and CD4+ cell counts  
  Fasunla AJ, Ogunbosi BO, Odaibo GN, Nwaorgu OGB, Taiwo B, Olaleye DO, Osinusi K, Murphy RL, Adewole IF, Akinyinka OO, AIDS, 1/1/2014
• The hearing future of Nigeria  
  Galster J, Olaleye D, Akinyinka O, Murphy R, Dhar S, Audiology Today, 1/1/2014
• Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation  
  Nordell AD, McKenna M, Borges AH, Duprez D, Neuhaus J, Neaton JD, INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee, J Am Heart Assoc, 1/1/2014
• Disposition of amodiagquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy  
  Scarsi KK, Fehintola FA, Ma Q, Aweeka FT, Darin KM, Morse GD, Akinola IT, Adedeji WA, Lindegardh N, Tarning J, Ojengbede O, Adewole IF, Taiwo B, Murphy RL, Akinyinka O..., J Antimicrob Chemother, 1/1/2014
• HIV-1 infected specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional...  
  Gach JS, Achenbach CJ, Chromikova V, Berzins B, Lambert N, Landucci G, Forthal DN, Katlama C, Jung BH, Murphy RL, PLoS One, 1/1/2014
• Missed opportunities for prevention of mother-to-child transmission of HIV (PMTCT) in Ibadan, Southwest Nigeria  
  Ogunbosi BO, Oladokun RE, Awolude O, Brown BJ, Adeshina OA, Kuti M, Taiwo B, Berzins B, Kyriacou DN, Chadwich EG, Osinusi K, Adewole IF, Murphy RL, World J AIDS, 1/1/2014
• Ultrsonographic measures of cardiovascular disease risk in antiretroviral treatment-naïve individuals with HIV infection  
  Stein JH, Brown TT, Ribaudo HJ, Chen Y, Yan M, Lauer-Brodell E, McComsey GA, Dube MP, Murphy RL, Hodis HN, Currier JS, AIDS, 1/1/2013
• Tuberculosis after 1 year of combination antiretroviral therapy in Nigeria: a retrospective cohort study  
  Akanbi MO, Achenbach CJ, Feinglass J, Taiwo B, Onu A, Pho MT, Agbagi O, Kanki P, Murphy RL, AIDS Res Hum Retrovir, 1/1/2013
• Transmitted antiretroviral drug resistance in newly HIV-infected untreated patients in Segou and Bamako Mali  
  Maiga AI, Fofana DB, Maiga AC, Diallo F, Ait-Arkhoub Z, Daou F, Cisse M, Sarro YD, Oumar AA, Sylla A, Taiwo B, Murphy R, Katlama C, Tounkara A, Marcelin AG, Calvez V, AIDS Res Hum Retrovir, 1/1/2013
• High-risk human papillomavirus among HIV-infected women with normal cervical cytology: a pilot study in Jos, Nigeria  
  Musa J, Taiwo B, Achenbach C, Olugbenga S, Berzins B, Sagay AS, Idoko JA, Kanki PJ, Murphy RL, Arch Gynecolo Obstet, 1/1/2013
• Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus co-infection in Nigeria  
  Hawkins C, Agbaji O, Ugoagwu P, Thio C, Auwal MM, Ani C, Okafo C, Wallender E, Murphy RL, Clin Inf Dis, 1/1/2013
• Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria  
  Agbaji O, Thio CL, Meloni S, Graham C, Muazu M, Nimzing L, Idoko J, Sankale JL, Ekong E, Murphy R, Kanki P, Hawkins C, J Acquir Immune Def Syndr, 1/1/2013
• Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naïve HIV-1 infected individuals  
  Brown TT, Chen Y, Currier JS, Ribaudo HJ, Rothenberg J, Dube MP, Murphy R, Stein JH, McComsey GA, J Acquir Immune Defic Syndr, 1/1/2013
• Adjuvant host-directed therapy with type 3 and 5 phosphodiesterase inhibitors, but not type 4, shortens the duration in tuberculosis treatment  
  Maiga M, Ammerman NC, Maiga M, Tounkara A, Siddiqui S, Polis M, Murphy RL, BIshai WR, J Infect Dis, 1/1/2013
• Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings  
  Adetunji AA, Achenbach C, Feinglass J, Darin KM, Scarsi KK, Ekong E, Taiwo BO, Adewole IF, Murphy R, J Int Assoc Physicians AIDS Care, 1/1/2013
• Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully-suppressed pre-treated patients infected with HIV-1  
  Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L, Fourn E, Duvivier C, Simon A, Courbon E, Murphy R, Flandre P, Peytavin G, Katlama C, RADAR Stu..., J Med Virol, 1/1/2013
• Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy  
  Jabs DA, Ahuja A, Van Natta M, Dunn JP, Yeh S, Studies of the Ocular Complications of AIDS Research Group, Ophthalmology, 1/1/2013
• The history of antiretroviral therapy and of its implementation in resource-limited areas of the world  
  Vella S, Schwartlander B, Sow SP, Eholie SP, Murphy RL, AIDS, 1/1/2012
• Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource limited settings: AIDS Clinical Trials Group Study A5...  
  Robertson K, Jiang J, Kumwenda J, Supparatpinyo K, Evans S, Campbell TB, Price R, Tripathy S, Kumarasamy N, La Rosa A; the 5199 study team, Santos B, Silva M, Montano..., Clin Infec Dis, 1/1/2012
• Dolutegravir for the treatment of HIV  
  Katlama C, Murphy R, Expert Opin Investig Drugs, 1/1/2012
• Combination nucléoside/nucléotide reverse transcriptase inhibitors for treatment of HIV infection  
  Akanbi MO, Scarci K, Taiwo B, Murphy RL, Expert Opin Pharmacother, 1/1/2012
• Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity  
  Maiga AI, Penugonda S, Katile D, Diallo F, Fofana DB, Berzins R, Maiga MY, Sylla A, Traore HA, Marcelin AG, Calvez V, Tounkara A, Bellosillo N, Murphy R, Taiwo B, J Acquir Immune Defic Syndr, 1/1/2012
• Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting  
  Maiga AI, Fofana DB, Cisse M, Diallo F, Maiga MY, Traore HA, Maiga IA, Sylla A, Fofana D, Taiwo B, Murphy R, Katlama C, Tounkara A, Calvez V, Marcelin A-G, J Antimicrob Chemother, 1/1/2012
• Host gene expression changes correlating with anti-HIV-1 effect in human subjects after treatment with peginterferon alfa-2a  
  Hubbard JJ, Greenwell-Wild T, Barrett L, Yang J, Lmepicki RA, Wahl SM, Asmuth DM, Murphy RL, Pollard RB, Kottilil S, J Infect Dis, 1/1/2012
• Join now to see all

Books/Book Chapters

• From the Ground Up: Building Comprehensive HIV/AIDS Care Programs in Resource-Limited Settings. 
  Chapter: Antiretroviral treatment failure, drug resistance, and management of therapy-experienced patients. 
  Page 89 - 108Taiwo B and Murphy REditors: Marlink R, Teitelman SJ.Elizabeth Glase Pediatric AIDS Foundation, Washington, DC2009
• Current Therapy of Infectious Disease. 
  Chapter: Corticosteroids, cytotoxic agents, and infection. 
  Page 615 - 621Taiwo B, Murphy REditors: Schlossberg D.Mosby, St. Louis, MOEdition 3rd,2008
• AIDS in Nigeria. 
  Chapter: Treatment and care of HIV disease. 
  Page 385 - 436Idoko J, Taiwo B, Murphy RLEditors: Adeyi O, Kanki P, Odutolu O, Idoko J.Harvard Center for Population and Developmental Studies, Cambridge, MA2006
• AIDS Therapy 
  Chapter: Amprenavir. 
  Page 225 - 235Murphy RLEditors: Dolin R, Masur H, and Saag M.Churchill-Livingstone, Philadelphia, PAEdition 2nd,2003
• Management of the HIV-Infected Patient 
  Chapter: Treatment of HIV infections. 
  Page 117 - 128Murphy REditors: Crowe S, Hoy J, and Mills J.Martin Dunitz, Ltd, LondonEdition 2nd,2002
• Current Therapy of Infectious Disease 
  Chapter: Corticosteroids, cytotoxic agents, and infection. 
  Page 356 - 358Lee JK, Murphy REditors: Schlossberg D.Mosby, St. Louis, MOEdition 2nd,2000
• AIDS Therapy. 
  Chapter: Amprenavir. 
  Page 188 - 197Murphy R and Kilby MEditors: Dolin R, Masur H, and Saag M.Churchill Livingstone, New York, NY1999
• Infectious Diseases. 
  Chapter: Practice strategies for initiating or changing antiretroviral therapy. 
  Murphy REditors: Armstrong D and Cohen J.Harcourt Brace, London1999
• APIC Infection Control and Applied Epidemiology. 
  Chapter: Occupational Blood Exposure. 
  Lee JK and Murphy R1999
• 12th World AIDS Conference-Clinical Science. 
  Chapter: Pharmacokinetic interaction between nevirapine and indinavir and correlation with antiviral activity in HIV-infected individuals. 
  Page 313 - 317Murphy RL, Sommadossi JP, Lamson M, Hall D, Myers M, and Dusek AMonduzzi Editore, Bolongna1998
• Principles of medical therapy in pregnancy. 
  Chapter: Helminthic infections in pregnancy. 
  Page 848 - 853Murphy RLAppleton and Lange, Stamford, CT1998
• Biologic and Clinical Basis of Infectious Diseases. 
  Chapter: Diagnosis and management of infection in the immunocompromised host. 
  Page 361 - 381Noskin GA, Phair JP, and Murphy RLEditors: Shulman ST, Phair JP, Peterson LR, and Warren JR.Saunders, PAEdition 5th,1997
• Clinical and Biological Basis of Infectious Disease. 
  Chapter: Sexually Transmitted Diseases. 
  Page 208 - 234Palella F and Murphy REditors: Shulman ST, Phair JP, Peterson LR, and Warren JR.Saunders, PAEdition 5th,1997
• HIV AIDS Infections. 
  Phair JP and Murphy RLHandbooks in Healthcare, Newtown, PA1997
• AIDS-Management der Erkrankung. 
  Chapter: A review of stavudine. 
  Page 272 - 273Murphy REcomed, Landsberg, Germany1996
• Current Therapy of Infectious Disease. 
  Chapter: Corticosteroids, Cytotoxic Agents and Infection. 
  Page 296 - 298Murphy REditors: Schlossberg, D.Mosby-Year Book, St. Louis, MO1996
• Clinician’s Manual on the Management of AIDS. 
  Murphy RL and Lange JMAScience Press Ltd, London1996
• McGraw-Hill Encyclopedia of Science and Technology 
  Chapter: Opportunistic infections. 
  Murphy RMcGraw-Hill, New York, NY1996
• Clinical and Biological Basis of Infectious Disease. 
  Chapter: Infection in the Compromised Host. 
  Page 394 - 405Murphy RLEditors: Shulman ST and Phair JP.Saunders, PAEdition 4th,1992
• Principles of Medical Therapy in Pregnancy. 
  Chapter: Helminthic Infections in Pregnancy. 
  Page 706 - 710Murphy RLAppleton & Lange, CT1992
• Join now to see all

Abstracts/Posters

• Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus co-infection: Nigeria.
  Agbaji O, Ugoagwu P, Murphy R, Thio C, Ani C, Okafo C, Auwal M, Wallender E, Hawkins C, 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3/3/2013
• Higher initial and persistent rate of virologic failure with tenofovir/emtricitiabine/nevirapine therapy in a Nigerian cohort.
  Scarsi K, Darin K, eisen G, Meloni S, Rawizza H, Okonkwo P, Murphy R, Kanki P, 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 3/5/2012
• The association between body composition, soluble and cellular immune activation biomarkers, and BMD in ART-naïve HIV-1+ persons: baseline results of ACTG study A5260s.
  Brown T, Currier J, Chen Y, Ribaudo H, Touw J, Rothenberg J, Dube M, Murphy R, Stein J, McComsey G, 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 3/5/2012
• TB risk, influence of CD4 cell count, and HIV RNA level after a year of first-line ART among HIV+ individuals: Jos, Nigeria.
  Akanbi M, Achenbach C, Feinglass J, Onu A, Kyriacou D, Taiwo B, Agbaji O, Ani A, Kanki P, Murphy R, 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 3/5/2012
• Patient-selected tresatment partners did not protect against development of resistance during NNRTI-based HAART in a randomized clinical trial.
  Taiwo B, Idoko J, Marcellin A-G, Otoh I, Reddy S, Iyaji P, Ogbaji O, Penugonda S, Agaba P and Murphy R, 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2/16/2010
• Comparison of immunologic and virlogic failure criteria in a large ART program in Nigeria.
  Rawizza H, Chaplin B, Rao R, Meloni S, Sankale J-L, Dieng-Sarr A, Ekong E, Murphy R, Kanki P, and APIN PEPFAR Team, 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2/16/2010
• Time to ART Resumption following Treatment Interruption is Shorter for Individuals Immunized with HIV-Recombinant Canarypox Vaccine (Vcp1452) Compared to Placebo: The ...
  Autran B, Costagliola D, Murphy R, Wincker N, Clotet B, Gatell J, Tubiana R, Staszewski S, Walker B, Katlama C, and ORVACS Study Group, Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2/25/2007
• ART Drug Resistance Mutations in ART-experienced and Newly Initiated Patients in Nigeria.
  Idigbe E, Chaplin B, Ekong E, Idoko J, Adewole I, Eisen G, Sankale JL, Murphy R, Kanki P, and APIN Plus/Harvard PEPFAR Team, Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2/25/2007
• Hepatitis E Virus Co-infection Affects Baseline HIV Parameters and HAART-related Hepatotoxicy Risk in an HIV-infected Nigerian Cohort.
  Idoko J, Meloni S, Muazu M, Hawkins C, Badung B, Gwamzi N, Kanki P, Murphy R, Ekong E, and Thio C, Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2/25/2007
• A Phase II, Randomize Placebo-controlled Study to Evaluate the Innumogenicity of 2 Schedules of an Homologous Prime-boost with the ALVAC-HIV vCP1452 in Chronically HIV...
  Katlama C, Wincker N, Costagliola D, Tubiana R, Murphy R, Clotet B, Gatell J, Staszewski S, Walker B, Autran B, and ORVACS Study Group, Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2/25/2007
• Evaluation of ART in the Harvard PEPFAR Treatment Program in Nigeria.
  Meloni S, Ekong E, Onwujekwe D, Okany C, Adewole I, Idehen C, Gaschau W, Idoko J, Murphy R, Kanki P, and APIN Plus/Harvard PEPFAR Team, Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2/25/2007
• Response to Kaletra-based Second-line Drug Regimen in HIV-1 Patients in Nigeria.
  Onwuegbuzie G, Idoko J, Agbaji O, Agaba P, Akintude L, Muazu M, Imade G, Sankale JL, Murphy R, and Kanki P, Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2/25/2007
• Peripheral and visceral fat changes following a treatment switch to a nonthymidine analogue or nucleoside-sparing regimen in patients with peripheral lipoatrophy: 48 ...
  Murphy R, Zhang J, Hafner R, Yarasheski K, Tashima K, Berzins B, Owens S, Shevitz A, Evans S, Tebas P and the ACTG A5110 Team, Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2/5/2006
• Effect of plasma preparation tubes vs standard EDTA tubes on viral “blips” in patients with optimally suppressed plasma HIV=1 RNA.
  Murphy R, Berzins B, Leake A, Till M, Stosor V, Stanton J, Palella F, Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2/22/2005
• Switching to a thymidine analog-sparing or a nucleoside-sparing regimen improves lipoatrophy: 24 week results of a prospective randomized clinical trial, AACTG 5110.
  Murphy R, Zhang J, Hafner R, Shevitz A, Tashima K, Yarasheski K, Forand J, Berzins B, Owns S, Evans S, Tebas P and the AACTG 5110 Study Team, Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2/22/2005
• Risk of cardiovascular disease in HIV-infected adults with immune reconstitution.
  Williams P, Wu J, Cohn S, Koletar S, McCutchen J, Murphy R, Currier J and the ACTG 362 Team, Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2/22/2005
• Potent anti-HIV activity of Reverset following 10 days of monotherapy in treatment-naïve individuals.
  Murphy RL, Schurmann D, Beard A, Schinazi R, Wagner F, Levy R, Otto M, Abstracts of the XVth International AIDS Conference, Bangkok, Thailand, 7/11/2004
• Fat Redistribution and metabolic study (FRAMS) in patients receiving a necueoside reverse transcriptase inhibitor, non-NRTI, or protease inhibitor-based regimen over 4...
  Murphy RL, Katlama C, Weverling GJ, Hoff F, Roubenoff R, Berzins B, Gatell J, Horban A, van Eeden A, Antunes F, Bijleveld E, Clotet B, Staszewski S, van Leeuwen R, Lan..., Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2/8/2004
• Tolerance and potent anti-HIV-1 activity of Reverset following 10 days of mono-therapy in treatment-naïve individuals.
  Murphy RL, Schurmann D, Beard A, Cartee L, Schinazi RF, Otto MJ, Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2/8/2004
• Risk factors for mortality in patients with AIDS in the era of HAART.
  Jabs D, Holbrook J, Clark R, Jacobson M, Kempen J, Murphy R, van Natta M and the Studies of Ocular Complications of AIDS Research Group, Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2/8/2004
• The effect of tenofovir on lopinavir/ritonavir trough concentrations in HIV-1-infected patients.
  Scarsi KK, Postelnick JM, Murphy RL, Final Program and Abstracts of the 8th World STI/AIDS Congress and 40th IUSTI World General Assembly, Punta del Este, Uruguay, 12/2/2003
• Antiretroviral drug toxicities.
  Murphy R, Final Program and Abstracts of the IXth International Antiviral Symposium and Workshop, Antalya, Turkey, 11/9/2003
• Pharmacokinetics, safety and antiviral activity of the nucleoside reverset following single doses in HIV-1 infected patients.
  Murphy R, Schurmann D, Kravec J, Eron J, Beard A, Cartee L, Hurwitz SJ, Erickson-Vitanen S, Leiotto DC, Schinazi RF, Stuyver L, Otto M, Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 7/13/2003
• CD4 cell increases through more than 4 years in antiretroviral-naïve HIV+ patients treated with lopinavir/ritonavir-based therapy.
  Kessler J, Heath-Chiozzi M, King M, King KR, Murphy R, Hicks C, Eron J, Gulick R, Glesby M, Wolfe P, Thompson M, White AC, Benson C, Albrecht M, Brun S, Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 7/13/2003
• HIV: nucleosides and nonnucleoside reverse transcriptase inhibitors in highly active antiretroviral therapy (HAART).
  Murphy R, Final Program and Abstracts of the Developments in Nucleic Acids, Atlanta, GA, 4/25/2003
• Join now to see all

Lectures

• AIDS 
  Feinberg School of Medicine, Northwestern University - 1/1/2014
• Sexually Transmitted Diseases 
  Feinberg School of Medicine, Northwestern University - 1/1/2014
• Combating Infectious Diseases in the Developing World (IID228) 
  Harvard School of Public Health - 1/1/2012
• Global Health Lecturer, Public Health and Population Science Course. 
  Northwestern University, Chicago, IL - 1/1/2006
• Clinical Care Options for HIV (Advisory Board Member and Lecturer) 
  1/1/1997
• Model Sexually Transmitted Diseases (Model Sexually Transmitted Diseases) 
  1/1/1996
• Join now to see all

Other

• Adverse effects of antiretroviral therapy in developing countries 
  Murphy RL, Taiwo B, Krakower D, Gandhi RT
  http://www.uptodate.com/contents/adverse-effects-of-antiretroviral-therapy-in-developing-countries
  UpToDate, Wolters Kluwer Health - 2012-11-05